Zimmer Biomet (NYSE:ZBH) Given New $117.00 Price Target at Citigroup

Zimmer Biomet (NYSE:ZBH) had its price objective hoisted by equities research analysts at Citigroup from $99.00 to $117.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical equipment provider’s stock. Citigroup‘s price target would suggest a potential upside of 9.27% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings upgraded Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Barclays upgraded Zimmer Biomet to a “hold” rating in a report on Wednesday, October 7th. Sanford C. Bernstein lifted their target price on Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a research report on Thursday. Canaccord Genuity Group lifted their target price on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Finally, UBS Group reiterated a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a research note on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $109.68.

Zimmer Biomet Trading Down 2.8%

Shares of Zimmer Biomet stock traded down $3.07 during trading hours on Thursday, hitting $107.08. The company’s stock had a trading volume of 3,623,454 shares, compared to its average volume of 2,266,772. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $112.54. The firm has a fifty day moving average of $94.90 and a 200-day moving average of $91.89. The stock has a market cap of $20.42 billion, a price-to-earnings ratio of 26.05, a P/E/G ratio of 2.33 and a beta of 0.50. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The company’s revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.90 EPS. Research analysts forecast that Zimmer Biomet will post 8.54 EPS for the current year.

Insiders Place Their Bets

In related news, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares of the company’s stock, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently made changes to their positions in ZBH. BlackRock Inc. acquired a new stake in Zimmer Biomet in the second quarter valued at about $1,344,282,000. State Street Corp boosted its position in shares of Zimmer Biomet by 0.6% during the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after purchasing an additional 52,044 shares in the last quarter. Primecap Management Co. CA purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth $328,578,000. Dimensional Fund Advisors LP grew its stake in shares of Zimmer Biomet by 1.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock worth $201,082,000 after purchasing an additional 24,208 shares during the period. Finally, Bank of America Corp DE acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth $187,480,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Zimmer Biomet beat third-quarter estimates, with adjusted EPS of $1.90 and revenue of $2.063 billion, up 3.1% year over year. The company also raised its full-year 2026 outlook; strong hip and sports medicine sales helped offset a weaker knee market. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its price target from $110 to $125 and maintained an outperform rating, signaling greater potential upside in the shares. Royal Bank of Canada recommendations
• Positive Sentiment: The CEO said the company is not seeing a slowdown in orthopedic procedures, which may support continued demand for its products. Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
• Neutral Sentiment: Wells Fargo raised its target to $113 but kept an equal-weight rating; Bernstein lifted its target to $107 while maintaining market perform. The higher targets are tempered by those cautious-to-neutral ratings. Wells Fargo recommendations
• Negative Sentiment: Adjusted earnings were flat year over year, while reported diluted EPS fell 13.8%. Weakness in knees and margin pressure remain headwinds, even as other product categories supported sales growth. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.